Analysts expect that Vericel Corp (NASDAQ:VCEL) will post earnings of ($0.11) per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Vericel’s earnings. The lowest EPS estimate is ($0.13) and the highest is ($0.08). Vericel posted earnings per share of ($0.16) during the same quarter last year, which would indicate a positive year-over-year growth rate of 31.3%. The company is scheduled to report its next quarterly earnings report on Tuesday, November 6th.

According to Zacks, analysts expect that Vericel will report full-year earnings of ($0.38) per share for the current financial year, with EPS estimates ranging from ($0.47) to ($0.30). For the next fiscal year, analysts forecast that the firm will report earnings of ($0.13) per share, with EPS estimates ranging from ($0.28) to ($0.02). Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Vericel.

Vericel (NASDAQ:VCEL) last issued its quarterly earnings results on Monday, August 6th. The biotechnology company reported ($0.12) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.12). Vericel had a negative return on equity of 37.86% and a negative net margin of 23.35%. The firm had revenue of $19.01 million during the quarter, compared to the consensus estimate of $18.51 million.

A number of equities research analysts have commented on the company. Needham & Company LLC reduced their target price on Vericel from $15.00 to $14.00 and set a “buy” rating for the company in a report on Wednesday, August 8th. BTIG Research reissued a “buy” rating and issued a $17.00 target price on shares of Vericel in a report on Tuesday, August 7th. LADENBURG THALM/SH SH raised Vericel from a “neutral” rating to a “buy” rating in a report on Monday, July 16th. BidaskClub downgraded Vericel from a “buy” rating to a “hold” rating in a report on Tuesday, June 26th. Finally, ValuEngine raised Vericel from a “buy” rating to a “strong-buy” rating in a report on Wednesday, May 2nd. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Vericel presently has a consensus rating of “Buy” and an average target price of $15.00.

Shares of NASDAQ VCEL opened at $11.50 on Friday. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.72 and a quick ratio of 7.48. Vericel has a 1-year low of $3.30 and a 1-year high of $14.75. The firm has a market cap of $551.17 million, a P/E ratio of -23.00 and a beta of 3.18.

In other news, Director Paul K. Wotton sold 30,000 shares of the firm’s stock in a transaction on Monday, June 18th. The stock was sold at an average price of $12.06, for a total value of $361,800.00. Following the completion of the transaction, the director now owns 5,000 shares in the company, valued at $60,300. The sale was disclosed in a document filed with the SEC, which is available at this link. 4.70% of the stock is currently owned by company insiders.

Several hedge funds have recently made changes to their positions in the company. Capital Fund Management S.A. purchased a new stake in Vericel during the 2nd quarter worth about $104,000. Quantitative Systematic Strategies LLC purchased a new stake in Vericel during the 2nd quarter worth about $108,000. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in Vericel during the 2nd quarter worth about $116,000. Commonwealth Equity Services LLC purchased a new stake in Vericel during the 2nd quarter worth about $123,000. Finally, Metropolitan Life Insurance Co. NY purchased a new stake in Vericel during the 2nd quarter worth about $128,000. Institutional investors and hedge funds own 52.13% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure.

See Also: Google Finance Portfolio

Get a free copy of the Zacks research report on Vericel (VCEL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.